Pharmacological analysis of Empagliflozin: Acting through the CaMKII pathway in type 2 diabetes and acute cardiovascular events

Guangyao Shao

Qingdao University, Ri Zhao, Shan Dong Province, China

Abstract

Background

Type 2 diabetes mellitus is a high-risk factor for acute cardiovascular events. Some reports show that Empagliflozin has a protective effect on cardiovascular events and diabetes mellitus, and Empagliflozin can act on the CaMKII pathway. However, the specific gene of action is not precise. Therefore, this study investigated the target genes of Empagliflozin by integrated gene analysis and molecular docking method to provide a theoretical basis for further elucidating the mechanism of action of Empagliflozin.

Method

In this study, we obtained 12 datasets from GEO, divided into experimental and validation groups, with a total of 376 samples. We then integrated CaMKII pathway-related genes from OMIM, NCBI, and genecards databases. We then intersected them with the differential genes we obtained to obtain 5 common genes and performed functional enrichment analysis. We then performed group comparisons in the validation set, and we obtained 2 clinically significant genes, followed by molecular docking analysis with pymol, autodock software. We obtained molecular docking models for the 2 genes.

Conclusion

In this study, we obtained CaMK2G and PPP1CA, genes associated with the CaMKII pathway and type 2 diabetes and acute cardiovascular events, by integrative gene analysis and validated their expression in the relevant dataset. We also derived that Empagliflozin acts on amino acid TRP-125 of CaMK2G gene and GLN-249 ASP-210 ASP-208 of PPP1CA through CaMKII pathway, thus acting on type 2 diabetes and acute cardiovascular events by molecular docking technique.
Background

Patients with type 2 diabetes are at increased risk of developing cardiovascular disease [1]. Empagliflozin may reduce mortality from cardiovascular events by affecting hemodynamic effects [2]. It has been shown that empagliflozin contributes to cardiovascular disease by acting on the CaMKII pathway, decreasing its activity and reducing CaMKII pathway-dependent calcium efflux [3]. However, the genes in which Empagliflozin acts on the CAMKII pathway have not been reported. The search for markers of Empagliflozin at the transcriptome level is essential to understand the mechanism of action of Empagliflozin. Therefore, this study was conducted to investigate and demonstrate the target genes of Empagliflozin by integrating bioinformatics techniques and molecular docking techniques.

Method

Data acquisition and processing

In this study, 12 datasets with a total of 376 samples (the specific information such as the origin of the tissue is shown in Table 1) were obtained from the Gene Expression Omnibus (GEO database, https://www.ncbi.nlm.nih.gov/geo/) [4], and differential gene analysis was performed using R language to draw heat maps and volcano maps. In this study, the data from the GEO database were screened. The screening criteria were as follows: 1. search with the keywords “type 2 diabetes” and “acute heart disease.” 2. restrict the entry type to series 3. restrict the study type to expression analysis of arrays. 4. the data retrieved had controlled. 5. the data retrieved had genetic samples. 6. the organisms were restricted to Homo sapiens.

Exclusion criteria were as follows: 1. The data retrieved had drug treatment or other confounding factors in the experimental group. 2. The data retrieved did not have genetic samples. 3. The data obtained from the survey did not have grouping information. 4. The data obtained by probing did not have grouping information. 5. The source of the samples was not Homo sapiens.

Table 1. Information of the dataset used for the study.

| GEO_ID    | tissue                        | platform | sample     | molecule | country  |
|-----------|-------------------------------|----------|------------|----------|----------|
| GSE48060  | blood                         | GPL570   | 21         | 31(MI)   | total RNA| USA      |
| GSE19339  | blood vessel                  | GPL570   | 4          | 4(MI)    | total RNA| Switzerland |
| GSE97320  | blood                         | GPL570   | 3          | 3(MI)    | total RNA| China    |
| GSE12643  | skeletal muscle               | GPL8300  | 10         | 10(T2D)  | total RNA| Denmark  |
| GSE13760  | arterial tissue               | GPL571   | 11         | 10(T2D)  | total RNA| Denmark  |
| GSE20966  | pancreatic                    | GPL1352  | 10         | 10(T2D)  | total RNA| USA      |
| GSE25724  | islets                        | GPL96    | 7          | 6(T2D)   | total RNA| Italy    |
| GSE29231  | biopsy samples of visceral adipose | GPL6947 | 12         | 12(T2D)  | total RNA| India    |
| GSE71416  | omental adipose               | GPL570   | 6          | 14(T2D)  | total RNA| USA      |
| GSE78721  | adipocytes and infiltration macrophages | GPL15207 | 62         | 68(T2D)  | total RNA| India    |
| GSE60993  | blood                         | GPL6884  | 7          | 10(NSTEMI)| total RNA| South Korea |
|           |                               |          |            | 7(STEMI) |          |          |
|           |                               |          |            | 9(UA)    |          |          |
| GSE61144  | blood                         | GPL6106  | 10         | 7(STEMI) | total RNA| South Korea |
|           |                               |          |            | 7(recovered STEMI) |          |          |

MI: myocardial infarction. T2D: type 2 diabetes. STEMI: ST-elevation myocardial infarction, NSTEMI: Non-ST-elevation myocardial infarction and UA: unstable angina. recovered STEMI: Blood samples from STEMI patients 7 days after initial percutaneous coronary intervention.

https://doi.org/10.1371/journal.pone.0270152.t001
We screened out the experimental group for differentially expressed gene analysis and the validation group for critical genes. The specific information is as follows (Table 1).

**Data analysis and identification of DEGs**

Quality control was performed on the datasets obtained from GEO. Subsequently, the R package "limma" was used to analyze variance between samples. P-values of genes and adj. p-values after hypothesis testing were obtained after correction. The meaning of the corrected P-value is the P-value obtained after hypothesis test calibration [5, 6]. Log2 (fold change) > 1.5 or -1.5 and a p-value of 0.05 were used as screening criteria.

To avoid the effect of differences in gene expression in different tissues on the analysis results, we used the original grouping method in the dataset. We performed the analysis of differential gene expression within the original dataset. For example, in the dataset GSE48060, the raw data were obtained from blood and grouped into MI and control groups. We analyzed the raw matrix data into the R language for differential gene expression comparison.

**Heatmap and volcano plot**

Heatmaps and volcano maps of differential genes were obtained using the heatmap package in R software.

**Enrichment analysis**

Metascape is an online functional enrichment analysis website. It mainly includes interactive enrichment and more [7]. WebGestalt is a tool that is very commonly used for feature enrichment analysis and contains user-uploaded data. It provides researchers with a more convenient way to enrich features [8]. We used the Metascape website and the webgestalt website to perform functional enrichment analysis of the more than 5037 genes we obtained and visualize them to observe the main biological functions of these differential genes and the primary pathways. The search was performed by: 1. It entered differential genes as keywords into the search box. 2 and limited their species to homo sapiens. 3. the Method of Interest in the webgestalt website was limited to over-representation analysis.

**Identification of core genes**

In order to obtain the maximum number of differential genes and avoid drug-induced gene count reduction as a confounding factor, our original dataset was not selected for patients using Empagliflozin or not using Empagliflozin. Instead, we selected samples of patients with the disease and normal controls.

The CaMKII Pathway was selected as a screening condition because it has been demonstrated that the CaMKII Pathway may be a pathway for the pharmacological effects of Empagliflozin in type 2 diabetes and acute myocardial infarction. To test the possibility of this hypothesis, we conducted the present study. There are no relevant experiments to illustrate the pharmacological pathway of Empagliflozin in type 2 diabetes mellitus and acute myocardial infarction. Therefore, this study sought to demonstrate the possibility of CaMKII Pathway as a pharmacological pathway of Empagliflozin in type 2 diabetes and acute myocardial infarction.

OMIM (http://omim.org) is an online database of genetic information used by clinicians, molecular biologists, and genomic scientists [9]. GeneCards (www.genecards.org) is an integrated database of gene information. It brings together genetic data from several considerable public resources, such as HGNC [10], NCBI [11], ENSEMBL [12], and UniProtKB [13], as
well as many other smaller resources [14]. GeneCards include genomic, proteomic, transcriptomic, disease, and functional data for known human genes [15].

The U.S. National Center for Biotechnology Information (NCBI) is an online database of genetic information. It includes the retrieval and storage of genomic data. It provides free downloadable data to a wide range of researchers [16]. We analyzed the common genes obtained by differential analysis with the CaMKII pathway-related genes obtained by OMIM database NCBI database genecards database. We selected the genes they contained in common, i.e., the intersection was taken.

Functional enrichment analysis of essential genes
To observe the main biological functions and significant pathways of the five essential genes, we entered these five gene names as keywords into the search box of the Metascape website and webgestalt website. The search was performed by: 1. We entered differential genes as keywords into the search box. 2. Limiting their species to homo sapiens. 3. The Method of Interest in the webgestalt website was limited to over-representation analysis. In addition, we obtained upstream miRNAs for five essential genes by using the mRNA-miRNA module of the online miRNA database StarBase (version 3.0; http://starbase.sysu.edu.cn/index.php) [17].

Verification of the hub genes
We used the dataset GSE60993 GSE61144 as the validation group, extracted the expression of five essential genes, and compared them in groups according to the clinical stage of their disease, using t-tests with p-values as a measure of test effectiveness.

KEGG pathway analysis
We performed a KEGG pathway analysis to observe the pathways enriched by the five essential genes. KEGG (https://www.kegg.jp/) is a comprehensive database, of which the PATHWAY database is widely used for gene pathway studies [18]. KEGG mapper is a visualization tool for the KEGG database, which allows the visualization of gene enrichment pathways [19]. We entered the names of five critical genes as keywords into the search box of KEGG Mapper and limited the search mode to hsa. We obtained visualization maps of the pathways enriched by five essential genes. Among them, the Diabetic cardiomyopathy pathway and the cAMP signaling pathway should be of most interest to us.

Molecular docking
Autodock is currently maintained by Scripps Research. autodock is a tool that can perform molecular docking. The study showed that the RMSD (root mean square deviation, a metric that evaluates the sampling power of each program) and prediction accuracy of autodock software are relatively high [20, 21]. We used the autodock tool to perform molecular docking studies to determine the effective molecules of Empagliflozin that could bind to the proteins transcribed from our screened target genes and thus exert their biological effects.

For this purpose, we entered Empagliflozin as a keyword in the PubChem website (http://pubchem.ncbi.nlm.nih.gov, a public database of active ingredients of small molecules and RNAi reagents is available) to retrieve its active molecule as a ligand [22]. We have downloaded the 2D structure of Empagliflozin. The conversion was performed in Chem3D software. The energy-minimized structure of Empagliflozin was calculated and saved using the MM2 method by clicking on the calculation module in the software. The minimum RMS gradient was set to 0.01. We then searched the UniProt database (http://sparql.uniprot.org/, a
database for storing protein information) with "CaMK2G" and "PPP1CA" as keywords to obtain the protein files of 1.7A and 2.25A as receptors, respectively [23]. We downloaded the 3D data files of CaMK2G and PPP1CA protein structures.

PyMOL is open-source software for displaying the 3D structure of molecules written by DeLano Scientific LLC. We used pymol software to remove water molecules and ligands from the obtained receptor files. We then used autodock software to add hydrogen atoms and create active pockets and molecular docking. We clicked on the Grid to adjust the range of active pockets of the protein 3D structure. The specific parameters were as follows: the number of points in X dimension was 50, the number of points in Y dimension was 60, the number of points in Z dimension was 52. the spacing was 1, the x center was -20.012, the Y center was -32.916, the Z center was -5.221, the energy range was 5, and the maximum number of models was 20. We then performed a semi-flexible docking approach for molecular docking.

Statistics analysis
We used the student’s t-test to see any differences between the two groups. We used the rgpubr R package and the ggplot2 R package. rgpubr package was used for calculations, and ggplot2 was used for visualization.

Results
Differential gene analysis
Quality control was performed on the dataset obtained from GEO. All downloaded datasets were normalized by the R affy package using a robust multi-array average normalization method. Subsequently, differences between samples were analyzed using the R package "limma" and visualized using a heat map package, and we obtained 10 heat maps and volcano maps. Next, we plotted the disturbance maps using the R language. We obtained 5037 shared genes, which means that these 5037 genes intersect the differential genes obtained from the differential analysis of all data sets (Figs 1 and 2A).

Enrichment analysis
Metascape is an online functional enrichment analysis website. It mainly includes interactive functional enrichment and more [7]. WebGestalt is a tool that is very commonly used for feature enrichment analysis and contains 12 and 155 175 feature categories and user-uploaded data. It provides researchers with a more convenient way to enrich features [8]. We used the Metascape website and the webgestalt website to perform functional enrichment analysis of the more than 5037 genes we obtained and visualize them to observe the main biological functions of these differential genes and the primary pathways. The main cellular component enriched by the 5037 differential genes analyzed through the webgestalt database is the membrane. The primary enriched molecular function is protein binding. The main enriched biological process is bioregulation. The 5037 differential genes analyzed from the Metascape database were mainly enriched for the biological process of cytokine-mediated signalling, and the main enriched cellular component was the intracellular membrane bundle organelle. The main enriched molecular function is RNA binding (Fig 2D–2G).

Identification of core genes
We analyzed the common genes obtained by differential analysis with the CaMKII pathway-related genes obtained by OMIM database NCBI database genecards database. We selected the genes they contained in common, i.e, the intersection was taken. As shown in the Venn
diagram, we obtained 5 shared genes. By taking the intersection of CaMKII-related genes from the three NCBI OMIM gene card databases and the 4294 differential genes we obtained using the GEO database analysis, we obtained five genes (Fig 2B).

Functional enrichment analysis of essential genes
To observe the main biological functions and significant pathways of the five essential genes, we entered these five gene names as keywords into the search box of the Metascape website and webgestalt website. Five important genes obtained from Metascape database analysis are enriched in calmodulin-binding and trans-chemical synapses. (Fig 2H–2J) In addition, we used the Starbase database to analyze the upstream miRNAs of five essential genes (Fig 2C).

Verification of the hub genes
We used the dataset GSE60993 GSE61144 as a validation group, extracted their expression about 5 essential genes, and compared them in groups according to the clinical stage of their disease, using a t-test and using the p-value as a measure of the effect of the test, we obtained
Fig 3. As shown in the Fig 3, the p-values of CaMK2G PPP1CA and PPFIA1 were less than 0.05, and their expression levels were consistent with the clinical features, so we considered CaMK2G PPP1CA and PPFIA1 as the most significant genes among the five essential genes. Notably, in the box plot of GSE60993, the expression of CaMK2G was higher in acute ST-segment myocardial infarction than in acute non-ST-segment myocardial infarction and higher than in normal myocardium. In the box plot of GSE61144, CaMK2G expression was more significant in acute myocardial infarction than in normal myocardium. After recovery, the expression was lower in acute myocardial infarction but still higher than in normal myocardium (Fig 3).

KEGG pathway analysis

We performed a KEGG pathway analysis to observe the pathways enriched by the five essential genes. KEGG (https://www.kegg.jp/) is a comprehensive database, of which the PATHWAY database is widely used for gene pathway studies. kegg mapper is a visualization tool for the
KEGG database, which allows visualization of gene enrichment pathways. We entered the names of five critical genes as keywords into the search box of KEGG Mapper and limited the search mode to hsa. Among them, the Diabetic cardiomyopathy pathway and the cAMP signalling pathway should be of most interest to us. Notably, in the CaMP pathway, CNGC forms CaMK and participates in the CaMP pathway, which transfers calcium ions to cells. In the pathway of regulation of TRP channels by inflammatory mediators. CaMKII is involved in regulating TRP channels by inflammatory mediators by interacting with TRPV1 protein. PPP1 is involved in regulating TRP channels by inflammatory mediators through interaction with TRPM8 protein. In the Diabetic cardiomyopathy pathway, CaMKII is involved in myocardial contraction by interacting with RyR2 protein and causing contractile dysfunction. PPP1 is involved in Cardiomyocyte death (Fig 4).

Molecular docking
We imported the receptor protein from UniProt into pymol software to remove water and ligand molecules. We then imported the new protein receptor file and ligand molecule file into autodock software to perform hydrogenation and molecular docking analysis. The binding energies of the ligands to the CaMK2G and PPP1CA proteins were -7.6 and -8.6, which means that they require very little power to bind to the ligand molecules, i.e. they bind efficiently to the ligand molecules. In addition, I also show the amino acid residues that bind the ligand molecule to the receptor molecule. Among them, the effective molecule of Empagliflozin binds by hydrogen bonding to residue TRP-215 of CaMK2G protein and by hydrogen bonding to residue GLN-249 ASP-210 ASP-208 of PPP1CA protein (Fig 4E and 4F).

The region is predicted to bind to empagliflozin in CaMK2G, and PPP1CA. The region has lower activation energy, which indicates that this region is more likely to bind to empagliflozin but does not indicate that binding would alter its catalytic function. Moreover, whether the...
catalytic process is changed or not requires experimental validation. At this stage, this study can only provide the theoretical basis for the binding of CaMK2G and PPP1CA to empagliflozin, but not experimental validation.

**Discussion**

Patients with type 2 diabetes are at increased risk of cardiovascular disease. Empagliflozin may reduce mortality from cardiovascular events by affecting hemodynamic effects.

It has been suggested that empagliflozin promotes cardiovascular illness by acting on the CaMKII pathway, decreasing its activity and reducing CaMKII pathway-dependent calcium efflux. However, those genes in which Empagliflozin acts explicitly on the CAMKII pathway have not been reported; therefore, the present study investigated and demonstrated the target genes of Empagliflozin by integrating bioinformatics and molecular docking techniques.

We performed quality control on the 10 experimental sets of data obtained by GEO, and subsequently, we performed differential gene analysis, which yielded 5037 significant differential genes. We then combined with OMIM database NCBI database genecards database to jointly analyze 5 shared genes. We performed functional enrichment analysis and KEGG pathway analysis to determine the biological functions of these five shared genes and the enriched pathways. We concluded that CaMK2G and PPP1CA are associated with the CaMKII pathway and diabetic cardiomyopathy. The t-test of the validation group showed that these two genes were correlated with the clinical stage of myocardial infarction. Therefore, we concluded that
CaMK2G and PPP1CA could be the target genes of Empagliflozin. Subsequently, we performed a molecular docking study. We verified that the active components of Empagliflozin have minimal binding energy to CaMK2G and PPP1CA, suggesting that they can bind to each other and that the energy required for binding is small.

Experimental studies in mice showed that activation of CaMK2G mediated the inhibition of ATF4 and TRB3 and thus improved hepatic insulin signalling [24]. It has also been demonstrated that prostaglandin F 2α promotes hepatic glucose production through the CaMKIIγ/p38/FOXO1 signalling pathway [25]. In mice, adenoviral vector-mediated experiments have shown that the CAMKII pathway regulates vascular smooth muscle cell proliferation and vascular remodelling [26]. Drug Study Shows Reduced Incidence of Cardiovascular Events in Patients with Type 2 Diabetes After Treatment with Empagliflozin [27]. In mice, Empagliflozin significantly reduced the activity of the CaMKII pathway [3]. In the present study, molecular docking analysis showed that the effective molecule of Empagliflozin required very little energy to bind to CaMK2G, suggesting that Empagliflozin may indeed interact with the CaMKII pathway-related CaMK2G gene and its transcriptional proteins to produce pharmacological effects.

Study shows that calcium is closely associated with vascular smooth muscle cells via the PP1 signalling pathway [28]. PPP1CA transcribes protein phosphatase 1 (PP1), a serine/threonine phosphatase. Increased PP1 activity is associated with the development of heart failure [29, 30]. Studies in mice have shown that knocking out the transcribed protein PP1β under the PPP1 gene increases the risk of ventricular remodelling and heart failure [31]. Mouse studies have demonstrated that ATG16L1 promotes autophagy by participating in the phosphorylation of the CSNK2-PPP1 complex, which protects cardiomyocytes. That PPP1 dephosphorylates ATG16L1, leading to autophagy inhibition and induction of apoptosis [32]. These are all studies of the PPP1 pathway associated with cardiovascular events. In the present study, the molecular docking analysis showed that the effective molecule of Empagliflozin required very little energy to bind to PPP1CA, suggesting that Empagliflozin may indeed interact with the CaMKII pathway-related PPP1CA gene and its transcribed protein to produce its drug effect.

In our study, the CaMKII pathway-associated CaMK2G PPP1CA screened by bioinformatics analysis had low activation energy with the active ingredient of Empagliflozin, suggesting that the active ingredient of Empagliflozin is likely to modify the activity of the CaMKII pathway by binding to CaMK2G PPP1CA and thus exert its effect on type 2 diabetes and acute cardiovascular events.

Conclusions
The present study obtained CaMK2G and PPP1CA, a gene associated with the CaMKII pathway and type 2 diabetes and acute cardiovascular events, by integrative gene analysis. We verified their expression in the relevant dataset, and we concluded that CaMK2G PPP1CA could bind to the active ingredient of Empagliflozin at low activation energy by molecular docking technique. We concluded that the clinical effects of Empagliflozin are associated with CaMK2G and PPP1CA in CaMKII pathway by the above analysis.

Supporting information
S1 File.
(RAR)

Author Contributions
Conceptualization: Guangyao Shao.
Data curation: Guangyao Shao.

Formal analysis: Guangyao Shao.

Investigation: Guangyao Shao.

Methodology: Guangyao Shao.

Project administration: Guangyao Shao.

Resources: Guangyao Shao.

Software: Guangyao Shao.

Supervision: Guangyao Shao.

Validation: Guangyao Shao.

Visualization: Guangyao Shao.

Writing – original draft: Guangyao Shao.

Writing – review & editing: Guangyao Shao.

References

1. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001 Sep; 44 Suppl 2:S14–21. https://doi.org/10.1007/pl00002934 PMID: 11587045

2. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care. 2016 May; 39(5):717–25. https://doi.org/10.2337/dc16-0041 PMID: 27208375

3. Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, et al. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018 Aug; 5(4):642–648. https://doi.org/10.1002/ehf2.12336 PMID: 30117720

4. https://www.ncbi.nlm.nih.gov/geo/

5. Benjamini Y, Hochberg Y. Controlling the false discovery rate—a practical and powerful approach to multiple testing. J R Stat Soc B. 1995; 57:289–300. URL:https://rss.onlinelibrary.wiley.com/doi/abs/10.1111,2517-6161.1995.tb02031.x

6. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001; 29:1165–1188.URL: https://www.jstor.org/stable/2674075

7. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019 Apr 3; 10(1):1523. https://doi.org/10.1038/s41467-019-09234-6 PMID: 30944313

8. Liao, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped U.I.s and APIs. Nucleic Acids Res. 2019 Jul 2; 47(W1):W199–W205. https://doi.org/10.1093/nar/gkz401 PMID: 31114916

9. Amberger JS, Bocchin CA, Schiettecatte F, Scot AF, Hamos. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015 Jan; 43(Database issue):D789–98. https://doi.org/10.1093/nar/gku1205 Epub 2014 Nov 26. PMID: 25428349

10. HGNC. [(1 August 2010, date last accessed)]. http://www.genenames.org/

11. Entrez gene. [(1 August 2010, date last accessed)]. http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene.

12. Ensembl. [(1 August 2010, date last accessed)]. http://www.ensembl.org/index.html.

13. Universal Protein Resource (UniProtKB) [(1 August 2010, date last accessed)]. http://www.uniprot.org/

14. GeneCards sources. [(1 August 2010, date last accessed)]. http://www.genecards.org/sources.shtml.

15. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, et al. GeneCards Version 3: the human gene integrator. Database (Oxford). 2010 Aug 5;2010:bq020. https://doi.org/10.1093/database/baq020 PMID: 20689021
16. NCBI Resource Coordinators. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2018 Jan 4; 46(D1):D8–D13. https://doi.org/10.1093/nar/gkx1095 PMID: 29140470

17. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-cRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014 Jan; 42 (Database issue):D92–7. https://doi.org/10.1093/nar/gkt1248 Epub 2013 Dec 1. PMID: 24297251

18. Kanehisa M. Enzyme Annotation and Metabolic Reconstruction Using KEGG. Methods Mol Biol. 2017; 1611:135–145. https://doi.org/10.1007/978-1-4939-7015-5_11 PMID: 28451977

19. Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein sequences. Protein Sci. 2020 Jan; 29(1):28–35. https://doi.org/10.1002/pro.3711 Epub 2019 Aug 29. PMID: 31423653

20. Wang Z, Sun H, Yao X, Li D, Xu L, Li Y, et al. Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power. Phys Chem Chem Phys. 2016 May 14; 18(18):12964–75. https://doi.org/10.1039/c6cp01555g Epub 2016 Apr 25. PMID: 27108770

21. Su M, Yang Q, Du Y, Feng G, Liu Z, Li Y, et al. Comparative Assessment of Scoring Functions: The CASF-2016 Update. J Chem Inf Model. 2019 Feb 25; 59(2):895–913. https://doi.org/10.1021/acs.jcim.8b00545 Epub 2018 Dec 11. PMID: 30481020

22. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Zhou Z, et al. PubChem’s BioAssay Database. Nucleic Acids Res. 2012 Jan; 40(Database issue):D400–12. https://doi.org/10.1093/nar/gkr1132 Epub 2011 Dec 2. PMID: 22140440

23. The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017 Jan 4; 45(D1):D158–D169. https://doi.org/10.1093/nar/gkw1099 Epub 2016 Nov 29. PMID: 27899622

24. Ozcan L, Cristina de Souza J, Harari AA, Backs J, Olson EN, Tabas I. Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling. Cell Metab. 2013 Dec 3; 18(6):803–15. https://doi.org/10.1016/j.cmet.2013.10.011 Epub 2013 Nov 21. PMID: 24268736

25. Saddouk FZ, Sun LY, Liu YF, Jiang M, Singer DV, Backs J, et al. Ca2+/calmodulin-dependent protein kinase II-γ (CaMKIIγ) negatively regulates vascular smooth muscle cell proliferation and vascular remodeling. FASEB J. 2016 Mar; 30(3):1051–64. https://doi.org/10.1096/fj.15-279158 Epub 2015 Nov 13. PMID: 26567004

26. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26; 373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720 Epub 2015 Sep 17. PMID: 26378978

27. Lipskaia L, Bobe R, Chen J, Turnbull IC, Lopez JJ, et al. Synergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca2+-ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cells. Circulation. 2014 Feb 18; 129(7):773–85. https://doi.org/10.1161/CIRCULATIONAHA.113.002565 Epub 2013 Nov 18. PMID: 24249716

28. Yamada M, Ikeda Y, Yano M, Yoshimura K, Nishino S, Aoyama H, et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J. 2006 Jun; 20(8):1197–9. https://doi.org/10.1096/fj.05-5299fje Epub 2006 Apr 23. PMID: 16627625

29. Aoyama H, Ikeda Y, Miyazaki Y, Yoshimura K, Nishino S, et al. Isoform-specific roles of protein phosphatase 1 catalytic subunits in sarcoplasmic reticulum-mediated Ca(2+)-mediated Ca(2+)-ATPase cycling. Cardiovasc Res. 2011 Jan 1; 89(1):79–88. https://doi.org/10.1093/cvr/cqv252 Epub 2010 Jul 31. PMID: 20675715

30. Liu L, Correll RN, Davis J, VagnozzJ RJ, York AJ, Sargent MA, et al. Cardiac-specific deletion of protein phosphatase 1β promotes increased myofilament protein phosphorylation and contractile alterations. J Mol Cell Cardiol. 2015 Oct; 87:204–13. https://doi.org/10.1016/j.yjmcc.2015.08.018 Epub 2015 Aug 31. PMID: 26334248

31. Song H, Pu J, Wang L, Wu L, Xiao J, Liu Q, et al. ATG16L1 phosphorylation is oppositely regulated by CSN2/casein kinase 2 and PPP1/protein phosphatase 1 which determines the fate of cardiomyocytes during hypoxia/reoxygenation. Autophagy. 2015; 11(8):1308–25. https://doi.org/10.1080/15548627.2015.1060386 PMID: 26083323